Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients
Abstract Background Ulcerative colitis is a common non-specific chronic disease. Supplementing probiotics has become an important method for the treatment of ulcerative colitis. This study aimed to explore the effect of supplementing bifid triple viable capsules on background mesalazine plus somatos...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12876-021-01887-2 |
id |
doaj-f2b4e4d6e7c3480a9a7c51a4abd5a62e |
---|---|
record_format |
Article |
spelling |
doaj-f2b4e4d6e7c3480a9a7c51a4abd5a62e2021-08-08T11:16:49ZengBMCBMC Gastroenterology1471-230X2021-08-0121111210.1186/s12876-021-01887-2Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patientsShuying Li0Yan Yin1Dan Xiao2Yong Zou3General Department, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan UniversityDepartment of Infection Management, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan UniversityDepartment of Gastroenterology, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan UniversityEmergency Department, Wuhan Emergency Medical CenterAbstract Background Ulcerative colitis is a common non-specific chronic disease. Supplementing probiotics has become an important method for the treatment of ulcerative colitis. This study aimed to explore the effect of supplementing bifid triple viable capsules on background mesalazine plus somatostatin on plasma inflammatory factors and T cell frequency in ulcerative colitis patients. Methods A total of 130 ulcerative colitis patients admitted to our hospital from August 2018 to March 2020 were included and divided into the experimental group (65 patients with mesalazine plus somatostatin and bifid triple viable capsules for treatment) and the control group (65 patients treated with mesalazine plus somatostatin) using the random number table method. Bifid triple viable bacteria capsules were given orally, 420 mg each time, with 3 times a day for 2 months. Results Before treatment, the plasma levels of IL-6, IL-8, hs-CRP, TNF-α, D-lactic acid, and endotoxin (ET), CD4+, CD8+, CD4/CD8 ratio, diamine oxidase (DA0), emotional ability, social ability, intestinal and systemic symptoms were not significantly different between the two groups (all P > 0.05). After treatment, the plasma levels of IL-6, IL-8, hs-CRP, and TNF-α decreased in both groups, and were lower in the experimental group than those in the control group (all P < 0.05). The levels of CD4+ and CD4/CD8 ratio increased, and were higher in the experimental group than those in the control group (P < 0.05); the CD8+ levels were reduced, and were lower in the experimental group than those in the control group (P < 0.05). The plasma D-lactic acid, ET, and DA0 levels were decreased, and were lower in the experimental group than those in the control group; emotional ability, social ability, intestinal and systemic symptoms were improved, and were higher in the experimental group than those in the control group (all P < 0.05). During the course of treatment, 2 cases of abdominal discomfort and 1 case of rash occurred in the experimental group, with an adverse event rate of 4.62% (3/65); 3 cases of abdominal discomfort and 2 cases of rash occurred in the control group, with an adverse event rate of 7.69% (5/65). Conclusion The supplementary treatment of bifid triple viable capsules can effectively enhance the curative effect in ulcerative colitis patients, reduce plasma inflammatory factors, and regulate T cell frequency, which is worthy of clinical application.https://doi.org/10.1186/s12876-021-01887-2MesalazineSomatostatinBifid triple viable capsulesUlcerative colitisPlasma inflammatory factorsT cell frequency |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shuying Li Yan Yin Dan Xiao Yong Zou |
spellingShingle |
Shuying Li Yan Yin Dan Xiao Yong Zou Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients BMC Gastroenterology Mesalazine Somatostatin Bifid triple viable capsules Ulcerative colitis Plasma inflammatory factors T cell frequency |
author_facet |
Shuying Li Yan Yin Dan Xiao Yong Zou |
author_sort |
Shuying Li |
title |
Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients |
title_short |
Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients |
title_full |
Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients |
title_fullStr |
Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients |
title_full_unstemmed |
Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients |
title_sort |
supplemental bifid triple viable capsule treatment improves inflammatory response and t cell frequency in ulcerative colitis patients |
publisher |
BMC |
series |
BMC Gastroenterology |
issn |
1471-230X |
publishDate |
2021-08-01 |
description |
Abstract Background Ulcerative colitis is a common non-specific chronic disease. Supplementing probiotics has become an important method for the treatment of ulcerative colitis. This study aimed to explore the effect of supplementing bifid triple viable capsules on background mesalazine plus somatostatin on plasma inflammatory factors and T cell frequency in ulcerative colitis patients. Methods A total of 130 ulcerative colitis patients admitted to our hospital from August 2018 to March 2020 were included and divided into the experimental group (65 patients with mesalazine plus somatostatin and bifid triple viable capsules for treatment) and the control group (65 patients treated with mesalazine plus somatostatin) using the random number table method. Bifid triple viable bacteria capsules were given orally, 420 mg each time, with 3 times a day for 2 months. Results Before treatment, the plasma levels of IL-6, IL-8, hs-CRP, TNF-α, D-lactic acid, and endotoxin (ET), CD4+, CD8+, CD4/CD8 ratio, diamine oxidase (DA0), emotional ability, social ability, intestinal and systemic symptoms were not significantly different between the two groups (all P > 0.05). After treatment, the plasma levels of IL-6, IL-8, hs-CRP, and TNF-α decreased in both groups, and were lower in the experimental group than those in the control group (all P < 0.05). The levels of CD4+ and CD4/CD8 ratio increased, and were higher in the experimental group than those in the control group (P < 0.05); the CD8+ levels were reduced, and were lower in the experimental group than those in the control group (P < 0.05). The plasma D-lactic acid, ET, and DA0 levels were decreased, and were lower in the experimental group than those in the control group; emotional ability, social ability, intestinal and systemic symptoms were improved, and were higher in the experimental group than those in the control group (all P < 0.05). During the course of treatment, 2 cases of abdominal discomfort and 1 case of rash occurred in the experimental group, with an adverse event rate of 4.62% (3/65); 3 cases of abdominal discomfort and 2 cases of rash occurred in the control group, with an adverse event rate of 7.69% (5/65). Conclusion The supplementary treatment of bifid triple viable capsules can effectively enhance the curative effect in ulcerative colitis patients, reduce plasma inflammatory factors, and regulate T cell frequency, which is worthy of clinical application. |
topic |
Mesalazine Somatostatin Bifid triple viable capsules Ulcerative colitis Plasma inflammatory factors T cell frequency |
url |
https://doi.org/10.1186/s12876-021-01887-2 |
work_keys_str_mv |
AT shuyingli supplementalbifidtripleviablecapsuletreatmentimprovesinflammatoryresponseandtcellfrequencyinulcerativecolitispatients AT yanyin supplementalbifidtripleviablecapsuletreatmentimprovesinflammatoryresponseandtcellfrequencyinulcerativecolitispatients AT danxiao supplementalbifidtripleviablecapsuletreatmentimprovesinflammatoryresponseandtcellfrequencyinulcerativecolitispatients AT yongzou supplementalbifidtripleviablecapsuletreatmentimprovesinflammatoryresponseandtcellfrequencyinulcerativecolitispatients |
_version_ |
1721216120588861440 |